NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M

NEOGENOMICS INC

Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.
Q4 net loss $14M (improved from $23M loss in Q4'22); Adjusted EBITDA turned positive to $9M (vs -$1M).
Full year revenue $592M (+16% YoY); net loss $88M (improved from $144M); Adjusted EBITDA positive $3M (vs -$48M).
FY2024 guidance: revenue $650-660M (10-12% growth), net loss $(72)-$66M, Adjusted EBITDA $21-24M (600-700% improvement).
Cash and marketable securities $415M at year-end; no debt or dividend changes reported.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEOGENOMICS INC reported fourth fiscal quarter of 2023 and full year ended December 31, 2023 results: revenue $156 million, net income $14 million. Guidance initiated.

Period: fourth fiscal quarter of 2023 and full year ended December 31, 2023
Revenue: $156 million
Net income: $14 million
Guidance: initiated
Result: reported results

Exact text from the filing

forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.